Publications

Pubmed listing

click reference to open publication to new page

34. Seccareccia E, M Pinard, N Wang, S Li, J Burnier, D Dankort and P Brodt. The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis Oncogenesis 3(8): e116. (pdf)

33. Ramdzan ZM, R Pal, C Vadnais, G Vandal, C Cadieux, L Leduy, S Davoudi, L Yao, M Paquet, A Karnezis, M Paquet. D Dankort* and A Nepveu*. RAS Transformation Requires CUX1-Dependent Repair of Oxidative DNA Damage PLoS Biology. 12(3): e1001807. (pdf)

32. Vandal G, B Geiling and D Dankort. Ras effector mutants suggest a negative regulator inhibits lung tumor formation. PLoSone. 9(1):e84745. (pdf)

31. Geiling B, G Vandal, AR Posner, A deBryuns, KL Dutchak, S Garnett and D Dankort. A modular lentiviral and retroviral construction system to rapidly generate vectors for gene expression and gene knockdown in vitro and in vivo. PLoSone. 8(10):e76279. (pdf)

30. Kamata T, D Dankort, J Kang, S Giblett, CA Pritchard, M McMahon, AD Leavitt. (2013) Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-linege cells resistant to PLX4720. Mol Cancer Res. 11(12):1530-41. (pdf)

29. Mito JK, HD Min, Y Ma, JE Carter, BE Brigman, L Dodd, D Dankort, M McMahon, and DG Kirsch. (2013) Oncogene dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol. 229(1): 132-140. (pdf)

28. Wang J, T Kobayashi, N Floc’h, C Waugh Kinkade, A Aytes, D Dankort, C Lefebvre, A Mitrofanova, RD Cardiff, M McMahon, A Califano,, MM. Shen, and C Abate-Shen (2012) Braf activation cooperates with Pten loss to regulate c-Myc activation in advanced prostate cancer. Cancer Research 72(18):4765-76. (pdf)

27. Collisson EA, C Trejo, S Gu, JE. Korkola, L Heiser,R-P Charles, BA Rabinovich, B Hann, D Dankort, PT Spellman, W Philips, JW Gray, M McMahon (2012) A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. Cancer Discovery 2(8):685-93. (pdf)

26. Vredeveld LCW, PA Possik, M Smit, K Meissl, C Michaloglou, HM Horlings, A Ajouaou, PC Kortman, D Dankort, M McMahon, WJ Mooi and DS Peeper (2012) Abrogation of oncogene-induced senescence by pi3k pathway activation contributes to melanomagenesis. Genes & Development 26(10):1055-69. (pdf)

25. Damsky WE, DP Curley, M Santhanakrishnan, LE Rosenbaum, JT Platt, BE Gould Rothberg, MM Taketo, D Dankort, DL Rimm, M McMahon, M Bosenberg (2011) β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell 20(6):741-54.

24. Charles, RC, G Iezza, E Amendola, D Dankort & M McMahon (2011) Mutationally activated BRAFV600E elicits papillary thyroid cancer in the adult mouse. Cancer Research 71(11):3863-71. (pdf)

23. Revet I, L Feeney, S Bruguera, W Wilson, TK Dong, D Oh, D Dankort, & JE Cleaver (2011) The functional relevance of γH2Ax in the DNA damage response to UV irradiation and other DNA damaging agents. Proc Natl Acad Sci 108(21): 8663-7. (pdf)

22. Held, MA, D P Curley, D Dankort, M McMahon, V Muthuswamy, and M W Bosenberg (2010) Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Research 70(1): 388-97. (pdf)

21. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE, You MJ, Depinho RA, McMahon M, Bosenberg M. (2009) BRafV600E expression combined with Pten silencing cooperates to induce metastatic melanoma Nature Genetics 41(5): 544-52. (pdf)

20. Dankort D, Filenova E, Collado M, Serrano M, Jones K and M McMahon (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes & Developmentl 21(4): 361-6. (pdf)

19. Kim H, R Chan, DL Dankort, D Zuo, M Najoukas, M Park, WJ Muller. (2005) The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene 24(51): 7599-607. (pdf)

18. Khoury H, MA Naujokas, D Zuo, V Sangwan, MM Frigault, S Petkiewicz, DL Dankort, WJ Muller, and M Park. (2005) HGF Converts ErbB2/Neu Epithelial Morphogenesis to Cell Invasion. Mol Biol Cell 6(6): 550-61. (pdf)

17. Loureiro RM, AS Maharaj, D Dankort, WL Muller, PA D'Amore. (2005) ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. Biochem Biophys Res Commun. 326(2): 455-65.

16. Chan R, WR Hardy, D Dankort, MA Laing & WJ Muller. (2004) Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development 131: 5551-60. (pdf)

15. Marone R, D Hess, D Dankort, WJ Muller, NE Hynes, and A Badache. (2004) Memo mediates ErbB2-driven cell motility. Nat Cell Biol 6(6): 515-522. (pdf)

14. Saucier C, H Khoury, K-MV Lai, P Peschard, D Dankort, MA Naujokas, J Holash, GD Yancopoulos, WJ Muller, T Pawson and M Park. (2004) The Shc adaptor protein plays a critical role in VEGF induction by the Met and ErbB2 receptor tyrosine kinases: A critical function of Shc for early onset of tumor angiogenesis. Proc Natl Acad Sci 101(8): 2345-50. (pdf)

13. Settle M, MD Gordon, M Nadella, D Dankort, W Muller and JR Jacobs. (2003) Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model. Oncogene 22: 1916–1926. (pdf)

12. Dankort D, N Jeybala, N Jones, DJ Dumont, and WJ Muller. (2001) Multiple ErbB-2/Neu phosphorylation sites mediate transformation through distinct effector proteins. J. Biol Chem 276: 38921-38928. (pdf)

11. Dankort D, B Maslikowski, N Warner, N Kanno, H Kim, Z Wang, MF Moran, RG Oshima, RD Cardiff and WJ Muller. (2001) Grb2 and Shc adapter proteins play distinct roles in ErbB 2/Neu-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol 21(5): 7068-7077. (pdf)

10. Khoury H, DL Dankort, S Sadekova, MA Naujokas, WJ Muller and M Park. (2001) Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene 20(7): 788-99. (pdf)

9. Dankort D and WJ Muller. (2000) Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene 19(8): 1038-44. (pdf)

8. Siegel PM, DL Dankort and WJ Muller. (2000) Oncogene mediated signal transduction in transgenic mouse models of human breast cancer. Adv Exp Med Biol 480: 185-194.

7. Dankort DL, Z Wang, V Blackmore, MF Moran and WJ Muller (1997) Distinct tyrosine autophosphorylation sites negatively and positively modulate Neu-mediated transformation Mol Cell Biol 17(9): 5410-5425. (pdf)

6. Muller WJ, Dankort DL, PM Siegel and MA Webster (1997) Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer. Endocrine-Related Cancer 4: 75-84. (xxx)

5. DL Dankort and WJ Muller. (1997) TKB1 cells identify receptor tyrosine kinase interacting proteins. Strategies 12(1): 8-10. (xxx)

4. D Dankort and WJ Muller. (1996) Transgenic models of breast cancer metastasis In Mammary Tumor Cell Cycle, Differentiation and Metastasis, 71-88. Eds. R Dickson and ME Lippman. Kluwer Academic Publishers. (pdf)

3. Muthuswamy SK, PM Siegel, DL Dankort, M Webster and WJ Muller. (1994) Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity Mol Cell Biol 14(1): 735-743. (pdf)

2. Siegel PM, DL Dankort, WR Hardy and WJ Muller. (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors Mol Cell Biol 14(11): 7068-7077. (pdf)

1. Rowely RB, JM Lee, H Corbell, R Charbonneau, K Jue, DL Dankort and PE Branton. (1993) Isolation of chicken phosphotyrosyl phosphatase cDNA sequences and identification of a brain-species related to human PTPz Cell Mol Biol Res 39(3): 209-219. (xxx)

Dr. David Dankort

David Dankort received his PhD in Biology from McMaster University, where he biochemically and genetically dissected the oncogenic signals emanating from the ErbB2/Neu receptor tyrosine kinase (RTK). As a research assistant in the same lab he generated several ErbB2 transgenic models of breast cancer and uncovered a metastatic specific pathway from the ErbB2 RTK. He then went on to develop sophisticated genetically engineered mouse models of lung cancer and melanoma as a General Motors Cancer Research Postdoctoral Fellow in Martin McMahon’s lab at the UCSF Comprehensive Cancer Center. As an Associate Professor in the Department of Biology at McGill, a member of the Developmental Biology Research Initiative and an Associate Member of the Goodman Cancer Research Centre, Dr. Dankort is using genetically engineered mouse models to study cell growth control and metastasis in a whole organism.